

AD _____

Award Number: DAMD17-03-1-0476

TITLE: New Structural Approaches to Understanding the Disease Related Forms
of the Prion Protein

PRINCIPAL INVESTIGATOR: Dr. David E. Wemmer

CONTRACTING ORGANIZATION: Regents of the University of California
Berkeley CA 94720

REPORT DATE: January 2007

TYPE OF REPORT: Final Addendum

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the
author(s) and should not be construed as an official Department of the Army
position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				<i>Form Approved</i> OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-01-2007		2. REPORT TYPE Final Addendum		3. DATES COVERED (From - To) 15 Jun 06 - 14 Dec 06	
4. TITLE AND SUBTITLE New Structural Approaches to Understanding the Disease Related Forms of the Prion Protein				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER DAMD17-03-1-0476	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Dr. David E. Wemmer E-Mail: dewemmer@LBL.gov				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Regents of the University of California Berkeley CA 94720				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The mouse prion protein peptide (residues 89-143 with the substitution of Leu for Pro at residue 101) induces prion disease in sensitized mice. Samples of this peptide, isotopelabeled with 15N, were prepared by expression of a fusion in E.coli, cleaved to yield an unmodified peptide, and then fibrillized. Hydrogen exchange was allowed to occur in the fibrils for periods from 1 hour to 6 weeks, repeating initial experiments to verify the exchange behavior. The extent of exchange was monitored using peak intensities in 15N-1H HSQC nuclear magnetic resonance spectra in DMSO/D2O/TFA solutions. The results are consistent with previous measurements that we did. Analogous experiments were also done with unlabeled peptide in fibrils with the analysis done by mass spectroscopy. Fragmentation was improved relative to previous experiments by using a combination of two proteases. With the improved coverage it was possible to show that the same protected regions as determined by NMR could be identified.					
15. SUBJECT TERMS prion protein peptide, solid state NMR, hydrogen exchange, mass spectroscopy					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			USAMRMC
			UU	7	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover.....	1
SF 298.....	2
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	6
Reportable Outcomes.....	6
Conclusions.....	7
References.....	7
Appendices.....	N/A

INTRODUCTION

The central effort in this project has been the elucidation of the conformation of the prion protein fragment containing residues 89-143 in fibrils (previously demonstrated to induce prion disease upon injection into mice, Kaneko et al., 2000). By probing the exposure of amides using hydrogen exchange, detected both with NMR and mass spectroscopy we are enabling a comparison of the *in vitro* generated peptide and protein models with real prions produced *in vivo*. Of particular interest is to determine the relationship between core structure features and strain behavior. Understanding the fundamental steps of initiation and propagation of the disease associated conformation may lead to new methods for preventing conversion to the pathogenic form. The experimental work has continued to confirm and extend hydrogen exchange of backbone amides, detected both with NMR and mass spectroscopy. Samples are mouse prion protein residues 89-143 containing a P to L substitution at residue 101 (a mutation that is associated with disease). This remains the simplest bioactive model for prion disease. Samples were prepared both through chemical synthesis of the 55 residue peptide using standard solid-phase methods, and through expression of a fusion peptide in *E.coli* cells that is then purified and cleaved to give the native 55 residue peptide.

BODY

Production of PrP(89-143)P101L (=P₅₅) samples

The protocols we have applied for preparing samples in *E.coli* have continued to work well. For the work during this extension period, we have done expression with ¹⁵N ammonia to obtain uniformly ¹⁵N labeled samples for NMR detected hydrogen exchange. Unlabeled fibrils were made and handled in the same way for mass spectroscopy detected hydrogen exchange. Additional unlabeled peptide was also sent to another lab (Stubbs at Vanderbilt) that has been making magnetically ordered fibrils for diffraction work, but which would also be useful for solid state NMR.




NMR based quenched hydrogen exchange of PrP 89-143 P101L

To make sure that the NMR detected hydrogen exchange was giving reliable and reproducible results, we repeated the exchange measurements on ¹⁵N labeled fibrils using the same approach described in previous reports. Briefly protonated fibrils were prepared by aggregation in phosphate buffered saline with acetonitrile in the cold for 3 weeks, then were collected, resuspended in pD 7.5 10 mM phosphate buffer and incubated at room temperature. Fibrils were pelleted, washed with cold D₂O, then lyophilized. The dry fibrils were then dissolved in DMSO with 5% D₂O, 0.03% TFA-D, and analyzed by NMR. Assignments were described in previous reports. The results of these experiments were very similar to those reported previously, verifying the slowly exchanging amides (those in hydrogen bonds in the fibrils), and the multiexponential decay seen for some residues. These experiments show that the approach is reproducible.

Mass spectroscopic hydrogen exchange of PrP 89-143 P101L

Samples of unlabeled fibrils were prepared in the same way that the ¹⁵N labeled ones were, and then were subjected to the same exchange treatment. However in this case the samples were frozen, then taken to UCSD for analysis using an automated system in the laboratory of Prof. Virgil Woods (Englander et al., 2003). Previous experiments used


only a pepsin column for fragmenting the PrP peptide, but the number of fragments obtained was relatively low. To improve the fragmentation a second column, with fungal protease XIII was added in series to further fragment the initial pepsin peptides. Many different conditions were tested (different concentrations of denaturant, different denaturant and for increasing times of digestion). In fact many more peptides were generated. These were separated on the in-line C18 reverse phase HPLC column, and the eluant was run directly into the mass spectrometer to detect the mass change. Experiments were first done with non-deuterated peptide, and secondary fragmentation was done in the mass spectrometer to get a reliable identification of the peptides being observed. Although there is overlap in elution time, the separation of different peptides in the mass dimension reduces the overlap problems for the analysis. Once the peptides were identified, and the optimum digestions conditions were determined then the experiments were repeated using peptide that from fibrils that had been exposed to D₂O for exchange in, for variable amounts of time. These were then dissolved in denaturant, and subjected to the same fragmentation and mass measurements as for the unlabeled peptide. As expected, as deuterium exchanges in the peptides increase in their average mass. By comparing different peptides it is possible to localize the regions which have the most amides that are protected against exchange. The analysis of these data is consistent with the same regions as seen in the NMR detected experiments having the highest level of protection against exchange. The mass spectra were analyzed to quantify the extent of exchange observed. To do this a



Top: schematic of the system used for proteolytic fragmentation and mass spectroscopic hydrogen exchange determination. Middle: mass spec total ion chromatogram showing the profile of elution times for peptide fragments. Bottom: peptide map, bars indicating peptides that were observed. Dark bars indicate peaks that were clearly identifiable based on masses of fragments, lighter bars also identified but with less verification.

determination of the level of ‘back exchange’ during the process of fragmentation and separation needs to be determined. A measurement was therefore also done with fully deuterated peptide (not fibrilized). However the measurements suggested that the level of deuteration was less than

expected, so this determination will have to be redone. Samples have been prepared for a repeat run of both the exchange in and the control for back exchange. These experiments will give a more accurate determination of the number of amides protected against exchange but should not change the determination of the residues that are protected against exchange. With the peptide fragmentation observed in these experiments the localization of protected amides should be possible to within 5-10 amino acids, depending on the specific region and level of fragmentation. Experiments with the full length prion protein should make possible a comparison of protected regions to determine whether the hydrogen bonding in the *in vivo* PrP aggregated material, on in other *in vitro* aggregated peptide models is the same as in this small model system. Comparison of different strains may also be informative.



Mass spectra of a peptide fragment from PrP 89-101, +2 charge state. Top: no deuteration shows the natural abundance isotope distribution; Bottom: after deuteration, for this peptide about 7 deuterons (on the average) have been exchanged in.

KEY RESEARCH ACCOMPLISHMENTS

- repeated a full set of hydrogen exchange measurements on P₅₅ peptide in fibrils, using NMR verifying the reliability of the measurements.
- carried out a set of hydrogen exchange measurements using mass spectroscopy after improving the fragmentation. Reasonable localization was possible, and the data verified that protection against exchange occurred in the same regions as observed by NMR.

REPORTABLE OUTCOMES

A paper is being written on the results of the hydrogen exchange measurements, publication of the NMR results will wait until the complementary results from the mass spectroscopy based measurements are completed.

CONCLUSIONS

We have verified the reliability of the NMR based hydrogen exchange measurements on fibrils of PrP 89-143 P101L. We have now demonstrated that complementary measurements can be done with mass spectroscopy, with a sufficient level of fragmentation that regions protected against exchange can be identified. The first set of measurements are consistent with the results from NMR. The mass spectroscopy approach have good potential to be applied to longer PrP constructs, and in particular natural PrP forms that cannot be prepared in isotope labeled forms.

REFERENCES

Kaneko, K., Ball, H.L., Wille, H. Zhang, H., Groth, D., Torchia, M., Tremblay, P., Safar, J., Prusiner, DeArmond, S.B., Baldwin, M.A., Cohen, F.E. A Synthetic Peptide Initiates Gerstmann-Sträussler-Scheinker (GSS) Disease in Transgenic Mice. *J. Molec. Biol.* **295**, 997-1007 (2000).

Englander, J.J., Del Mar, C., Li, W., Englander, S.W., Kim, J.S., Stranz, D.D., Hamuro, Y., Woods, V.L. Jr. Protein structure change studied by hydrogen-deuterium exchange, functional labeling, and mass spectrometry. *Proc. Natl. Acad. Sci.* **100**, 7057-7062 (2003).